Managing Bone Marrow Failure in Countries with Restricted Resources

Read full text Summarise with VIRAT
Authors: Raheel Iftikhar, Carmem Bonfim, Moosa Patel, Hazzaa Abdulla Alzahrani, Adetola A. Kassim, Mahmoud Deeb Aljurf
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Managing aplastic anemia (AA) in resource-limited countries poses significant challenges due to inadequate diagnostic infrastructure, financial constraints, limited access to immunosuppressive therapy (IST), and few transplant centers. This chapter addresses the epidemiological variations, diagnostic hurdles, and practical therapeutic strategies tailored to constrained environments. With a younger age of presentation, limited availability of matched unrelated donors (MUDs), and reliance on family-based donors, management often necessitates adaptation. Cyclosporine (CsA) monotherapy, androgen therapy, and supportive care serve as critical alternatives when standard triple immunosuppression is unavailable. Matched related donor hematopoietic stem cell transplantation (MRD-HSCT) is often more feasible than immunosuppressive therapy in these settings. Haploidentical HSCT is gaining traction as a viable alternative due to broader donor availability. Strategic resource allocation, early referral, and regional collaboration are crucial to optimizing care. Despite limitations, survival outcomes of 70%–80% are achievable with a tailored approach, demonstrating that improved outcomes in AA are possible even in restricted-resource settings.

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Hematological disorders and diagnostics Blood disorders and treatments

Publication details

Journal / source
Springer eBooks
Pages
361–372
Publication date
25 March 2026
Language
EN
Document type
Book chapter